Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 238   

Articles published

JNJ 142.89 +0.29 (0.20%)
price chart
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing ...
ATLANTA—Johnson & Johnson's Janssen unit has found plenty of success moving Darzalex earlier and earlier into multiple myeloma therapy, and it now has data that could help it win a coveted spot in first-line treatment.
Johnson & Johnson: DARZALEX´┐Ż (daratumumab) Combination Regimen ...  The Wall Street Transcript
(daratumumab) Presented at ASH 2017 Show Feasibility of Subcutaneous Use and ...  Business Wire (press release)
130 years of history on display at Johnson & Johnson
Johnson & Johnson has been a household name for more than 100 years and a part of the New Brunswick community since its inception.
The Outlook For Johnson & Johnson's Immunology Drug Business
Johnson & Johnson's immunology portfolio, which primarily consists of Remicade, Simponi and Stelara, accounts for around 15% of the company's value, according to our estimates.
As Johnson & Johnson holds off US biosims, Remicade's European ...  FiercePharma
CertaDose Wins Johnson & Johnson Innovation Award for Advancing Safety in ...
We are honored to have Johnson & Johnson Innovation recognize our company's potential, and we look forward to making pediatric dosing errors a thing of the past.
Johnson & Johnson (JNJ) Management Presents at Citi Global Healthcare Conference
Before we begin, please be aware that some statements made today may be considered forward-looking statements or utilize non-GAAP measures.
Dividend stats on Johnson & Johnson
Johnson & Johnson's record of rising dividend payments dates back to the 1960s, and the company has done an excellent job of producing consistent dividend growth regardless of overall macroeconomic conditions or the particular environment the ...
Johnson & Johnson: Reliable Dividend Clipper
It's always fun to revisit a winning trade, and so I'm more chipper than usual talking about Johnson & Johnson (JNJ).
Johnson & Johnson (JNJ) call put ratio 4.4 calls to 1 put as shares pull ...  StreetInsider.com
Johnson & Johnson (JNJ) Closes 0.74% Down on the Day for December 07  Equities.com
Will 2018 Be Johnson & Johnson's Best Year Yet?
I think Johnson & Johnson will likely have its best year ever in some ways. For example, J&J's highest level of revenue ever for a year was set in 2014, when the company made $74.3 billion.
Johnson & Johnson's JLABS looks east as it lands in Shanghai
JLABS @ Shanghai is a 4,400-square-meter facility set to be located in Shanghai's Zhangjiang Hi-Tech Park; doors open in the second quarter of 2019.
Johnson & Johnson Innovation Announces Launch of JLABS @ Shanghai in ...  PR Newswire (press release)
Better Buy: Pfizer Inc. vs. Johnson & Johnson
Johnson & Johnson has its own challenges, with sales for its top-selling drug Remicade declining due to biosimilar competition (including Pfizer's Inflectra).